Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01890590 · ClinicalTrials.gov registry record · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
A NA study of Renal Cell Carcinoma, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT01890590: Recruiting NA study of Renal Cell Carcinoma, sponsored by Beth Israel Deaconess Medical Center.
NCT01890590 is a NA study of Renal Cell Carcinoma that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 46 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01890590, a NA study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus potentially increasing the efficacy of radiation treatment. Currently, radiosurgery is commonly used for brain metastases, Stage I lung cancer, spine tumors, and localized prostate cancer. The purpose of this protocol is to evaluate the role of Radiosurgery for the treatment of clinically localized primary renal cell carcinoma.
Conditions Studied
Interventions
- DEVICE CyberKnife
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2013-07 |
| Est. Completion | 2025-03 |
| Phase | NA |
What NCT01890590 shows while recruiting
NCT01890590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which CyberKnife is the first listed.
NCT01890590 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01890590 about?
NCT01890590 is a clinical study titled "A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma". CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus potentially increasing the efficacy of radiati...
What is the current status of trial NCT01890590?
This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2013-07. Estimated completion is 2025-03.
What conditions does trial NCT01890590 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT01890590?
The interventions under investigation include: CyberKnife (DEVICE).
Who is sponsoring clinical trial NCT01890590?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01890590 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01890590's enrollment target sits among peer trials
46 82nd of 121 higher than 39 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
RECRUITING · NA
-
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
RECRUITING · NA
-
Evaluation of a Simple-Prep Controlled Embolic
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
- NCT04214184 · 46 participants · NA
Biomarkers of Increased Free Living Sleep Time
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia